Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 601–700 of 1,448
Ishida, K., Misawa, K., Nishimura, H., Hirata, T., Yamamoto, M., & Ota, N. (2020) · Nutrients · doi:10.3390/nu12020494 · Cited by 56
“Recent studies indicated that BBB-mediated clearance is a major route for Aβ elimination in the brain and that LRP1 may be a key receptor for Aβ clearance [39].”
BackgroundDesigning peptide nanoparticles for efficient brain delivery
Duro‐Castaño, A., Leite, D. M., Forth, J., Deng, Y., Matias, D., Noble-Jesus, C., & Battaglia, G. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.001 · Cited by 53
“Recently, using computer-aided design, a short RAP12 (EAKIEKHNHYQK, amino acids 251-262 of RAP) peptide was identified for LRP1-mediated transport across the BBB [227].”
BackgroundInfluentialVerdile, G., Yeap, B. B., Clarnette, R. M., Dhaliwal, S., Burkhardt, M. S., Chubb, S. A. P., De Ruyck, K., Rodrigues, M., Mehta, P. D., Foster, J. K., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-14208 · Cited by 51
Mettenburg, J. M., Webb, D. J., & Gonias, S. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106792200 · Cited by 53
Lipoprotein receptors in Alzheimer's disease
Andersen, O. M., & Willnow, T. E. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.09.002 · Cited by 41
A Vascular Connection to Alzheimer's Disease
Rhodin, J. A. G., & Thomas, T. R. (2001) · Microcirculation · doi:10.1080/713774033 · Cited by 53
Intravenous immunoglobulin and Alzheimer’s disease: what now?
Loeffler, D. A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-70 · Cited by 48
“Low-density lipoprotein receptor-related protein-1 (LRP1) is the main receptor for transporting Aβ out of the brain [60].”
BackgroundAmyloid‐beta is present in human lymph nodes and greatly enriched in those of the cervical region
Nauen, D. W., & Troncoso, J. C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12385 · Cited by 57
Alcohol, inflammation, and blood-brain barrier function in health and disease across development
Vore, A. S., & Deak, T. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2021.06.009 · Cited by 68
Abdallah, I. M., Al-Shami, K. M., Yang, E., Wang, J., Guillaume, C., & Kaddoumi, A. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00005 · Cited by 53
Stereo-seq of the prefrontal cortex in aging and Alzheimer’s disease
Gong, Y., Haeri, M., Zhang, X., Li, Y., Liu, A., Wu, D., Zhang, Q., Jazwinski, S. M., Zhou, X., Wang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54715-y · Cited by 60
“These observations align with previous research indicating that impaired A β clearance is a hallmark of AD samples 111,112 and a decrease in tau phosphatase activity in AD brains contributes to an imbalance in the protein phosphorylation/dephosphorylation system, culminating in NFT formation 113 .”
Impaired Insulin Signaling and Mechanisms of Memory Loss
Bloemer, J., Bhattacharya, S., Amin, R., & Suppiramaniam, V. D. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00013-2 · Cited by 57
Ezra, A., Rabinovich-Nikitin, I., Rabinovich‐Toidman, P., & Solomon, B. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150694 · Cited by 55
Santos, L. M., Rodrigues, D. F., Alemi, M., Silva, S. C., Ribeiro, C. A., & Cardoso, I. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00124 · Cited by 55
Behzadfar, L., Abdollahi, M. R., Sabzevari, O., Hosseini, R., Salimi, A., Naserzadeh, P., Sharifzadeh, M. S., & Pourahmad, J. (2017) · Metallomics · doi:10.1039/c7mt00075h · Cited by 53
Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles
Islam, Y., Leach, A. G., Smith, J. A., Pluchino, S., Coxon, C. R., Sivakumaran, M., Downing, J. E., Fatokun, A. A., Teixidò, M., & Ehtezazi, T. (2021) · Advanced Science · doi:10.1002/advs.202002085 · Cited by 57
One Year Follow up in Ischemic Brain Injury and the Role of Alzheimer Factors
Jabłoński, M., Maciejewski, R., Januszewski, S., Ułamek, M., & Pluta, R. M. (2011) · Physiological Research · doi:10.33549/physiolres.932186 · Cited by 56
Clusterin Associates Specifically with A β40 in Alzheimer's Disease Brain Tissue
Howlett, D. R., Hortobágyi, T., & Francis, P. T. (2013) · Brain Pathology · doi:10.1111/bpa.12057 · Cited by 51
Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease
Chiarini, A., Armato, U., Liu, D., & Dal Prà, I. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00134 · Cited by 51
“…monomers Insulin-like growth factor-1 receptor (IGF-1R) Giuffrida et al., 2012 Aβ42 monomers Low-density lipoprotein receptor-related protein 1 (LRP1) Shibata, 2000; Kanekiyo et al., 2013, 2012 Aβ42 monomers Low-density lipoprotein receptor (LDLR) Castellano et al., 2012 Aβ42 monomers Macrophage…”
BackgroundReale, M., Nicola, M. D., Velluto, L., D’Angelo, C., Costantini, E., Lahiri, D. K., Kamal, M. A., Yu, Q.-S., & Greig, N. H. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212113218 · Cited by 55
“Receptor mediated movement of soluble Aβ across the blood–brain barrier (BBB) is driven by transporters, such as the low-density lipoprotein receptor-related protein-1 (LRP-1) [17,18] for efflux, and the receptor for advanced glycation end products (RAGE) [19] for influx.”
Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities
Parent, M. J., Zimmer, E. R., Shin, M., Kang, M. S., Fonov, V., Mathieu, A. P., Aliaga, A., Kostikov, A. P., Carmo, S. D., Dea, D., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1346-17.2017 · Cited by 52
“…brain as evidenced by positron emission tomography (PET) with radiopharmaceuticals specific to fibrillary amyloid (Klunk et al., 2004) such as [18F]NAV4694 (Cselényi et al., 2012) and by the reduction of A concentration in the CSF (Shibata et al., 2000; Strozyk et al., 2003; Deane et al., 2008).”
BackgroundWojtunik‐Kulesza, K. A., Rudkowska, M., Kasprzak‐Drozd, K., Oniszczuk, A., & Borowicz, K. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147366 · Cited by 54
A new role for astrocytes: β-amyloid homeostasis and degradation
Nicoll, J. A. R., & Weller, R. O. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00109-6 · Cited by 51
Shi, M., Chu, F., Zhu, F., & Zhu, J. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-03003-5 · Cited by 54
“…action [11, 12], by which mAbs binding to Aβ in peripheral blood may alter the balance between circulation and brain Aβ levels, thereby enhancing outflow of soluble Aβ from the brain via low density lipoprotein receptor related protein 1 (LRP1) expressed on the blood brain barrier (BBB) [13, 14].”
BackgroundDownregulation of LPR1 at the blood–brain barrier in streptozotocin-induced diabetic mice
Hong, H., Liu, L. P., Liao, J. M., Wang, T. S., Ye, F.-Y., Wu, J., Wang, Y. Y., Wang, Y., Li, Y. Q., & Long, Y. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.03.001 · Cited by 53
“No significant differences of both Ab40 and Ab42 in brain cortex were found in diabetic mice at 1 week and e.”
BackgroundMethodInfluentialExploring the Virchow-Robin spaces function: A unified theory of brain diseases
Cherian, I., Beltran, M., Kasper, E. M., Bhattarai, B., Munokami, S., & Grasso, G. (2016) · Surgical Neurology International · doi:10.4103/2152-7806.192486 · Cited by 51
“It is well‐known that soluble Aβ can be removed from the brain by various clearance systems, such as cellular uptake following enzymatic activity, transport across the blood–brain barrier (BBB) and blood–cerebrospinal fluid barrier, and ISF bulk flow.[33,36]”
BackgroundApolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing
Bachmeier, C., Shackleton, B., Ojo, J., Paris, D., Mullan, M., & Crawford, F. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8318-6 · Cited by 50
“This apparent protection provides rationale for reports that an absence of apoE altogether leads to reduced Ab brain clearance (Shibata et al. 2000) and increased Ab levels in the brain (DeMattos et al. 2004; Dodart et al. 2002).”
A safer vaccine for Alzheimer’s disease?
Sigurdsson, E. M., Wısnıewskı, T., & Frangione, B. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00124-0 · Cited by 52
Self-citationKnockin’ on heaven’s door: Molecular mechanisms of neuronal tau uptake
De La‐Rocque, S., Moretto, E., Butnaru, I., & Schiavo, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15144 · Cited by 39
“In addition, the neuronal processing of Aβ and its clearance via the blood brain barrier are modulated by LRP1 (Fuentealba et al., 2010; Shibata et al., 2000).”
BackgroundEndothelin receptor antagonists: Potential in Alzheimer's disease
Palmer, J. C., & Love, S. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.008 · Cited by 52
Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease
Martiskainen, H., Haapasalo, A., Kurkinen, K. M., Pihlajamäki, J., Soininen, H., & Hiltunen, M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.789862 · Cited by 46
“LRP1 expression has been shown to decline with aging in the brains of both humans and mice, and this decline is further attenuated in AD [35,54,116,117], suggesting that the results obtained in LRP1-overexpressing models may not be relevant for AD pathology, but they may present constrains for therapeutic targeting of…”
BackgroundInfluentialShackleton, B., Crawford, F., & Bachmeier, C. (2016) · Fluids and Barriers of the CNS · doi:10.1186/s12987-016-0038-x · Cited by 45
“Another possible explanation for our observations is that LRP1 expression is known to be lower in AD patients [13, 39] and AD animals, including the PSAPP mice used in the current studies [40].”
Akhter, H., Huang, W.-T., van Groen, T., Kuo, H., Miyata, T., & Liu, R.-M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180241 · Cited by 51
Dehshahri, A., & Sadeghpour, H. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.05.006 · Cited by 51
Anastasio, T. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00016 · Cited by 49
Cellular Catabolism of Lipid Poor Apolipoprotein E via Cell Surface LDL Receptor-Related Protein
Narita, M., Holtzman, D. M., Fagan, A. M., LaDu, M. J., Yu, L., Han, X., Gross, R. W., Bu, G., & Schwartz, A. L. (2002) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a003282 · Cited by 48
Self-citationAmyloid-β Interacts with Blood-Brain Barrier Function in Dementia: A Systematic Review
Burgmans, S., van de Haar, H. J., Verhey, F. R. J., & Backes, W. H. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122155 · Cited by 46
Pan, Y., Short, J. L., Newman, S. A., Choy, K. H. C., Tiwari, D., Yap, C., Senyschyn, D., Banks, W. A., & Nicolazzo, J. A. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.03.007 · Cited by 52
Pericytes Across the Lifetime in the Central Nervous System
Bennett, H. C., & Kim, Y. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.627291 · Cited by 52
Haemopexin affects iron distribution and ferritin expression in mouse brain
Morello, N., Tonoli, E., Logrand, F., Fiorito, V., Fagoonee, S., Turco, E., Silengo, L., Vercelli, A., Altruda, F., & Tolosano, E. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00611.x · Cited by 52
Behl, M., Zhang, Y., Monnot, A. D., Jiang, W., & Zheng, W. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.05.024 · Cited by 50
Intracerebral haemorrhage in Down syndrome: protected or predisposed?
Buss, L., Fisher, E., Hardy, J., Nizetic, D., Groet, J., Pulford, L., & Strydom, A. (2016) · F1000Research · doi:10.12688/f1000research.7819.1 · Cited by 48
Vasilevko, V., Xu, F., Previti, M. L., Van Nostrand, W. E., & Cribbs, D. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2788-07.2007 · Cited by 48
“, 2004) and from the periphery into CNS through the receptor for advanced glycation end products (Shibata et al., 2000; Deane et al., 2003).”
BackgroundAccumulation of murine amyloid-β mimics early Alzheimer’s disease
Krohn, M., Bracke, A., Avchalumov, Y., Schumacher, T., Hofrichter, J., Paarmann, K., Fröhlich, C., Lange, C., Brüning, T., von Bohlen und Halbach, O., et al. (2015) · Brain · doi:10.1093/brain/awv137 · Cited by 47
McMillan, I. O., Li, J., & Wang, L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00247.2022 · Cited by 52
Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study
Salem, F., Ahammed, S. M., Hassaballah, A. S., & Omar, M. M. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s85302 · Cited by 47
Drug Access to the Central Nervous System in Alzheimer’s Disease: Preclinical and Clinical Insights
Mehta, D. C., Short, J. L., Hilmer, S. N., & Nicolazzo, J. A. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1522-0 · Cited by 51
Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer’s disease
D'Cunha, N. M., McKune, A. J., Panagiotakos, D. B., Georgousopoulou, E. N., Thomas, J., Mellor, D. D., & Naumovski, N. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1349032 · Cited by 47
“Damage to the BBB is associated with AD pathophysiology including accumulation of Aβ, in part due to reduced clearance from the brain (101), and BBB dysfunction has been observed in MRI analysis of hippocampus in individuals with mild cognitive impairment (MCI) (102).”
BackgroundHypertension Accelerates Alzheimer’s Disease-Related Pathologies in Pigs and 3xTg Mice
Shih, Y., Wu, S.-Y., Yu, M., Huang, S.-H., Lee, C.-W., Jiang, M.-J., Lin, P., Yang, T.-T., & Kuo, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00073 · Cited by 50
“RAGE and LRP1 are two essential transporters on the blood-brain barrier that mediate the influx and efflux of Aβ peptides, respectively (Shibata et al., 2000; Deane et al., 2003).”
BackgroundAlcendor, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051490 · Cited by 48
Updated Understanding of the Glial-Vascular Unit in Central Nervous System Disorders
Yao, D., Zhang, R., Xie, M., Ding, F., Wang, M., & Wang, W. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00977-9 · Cited by 49
“Unlike the glymphatic system, this pathway is claimed to flow in a reverse direction to that of the blood, and drains through penetrating arteries into the subarachnoid spaces [74, 75].”
BackgroundAkhter, H., Katre, A. K., Li, L., Liu, X., & Liu, R.-M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110512 · Cited by 50
“LRP1 expression/activity in the brain is also decreased with increasing age [25, 62].”
BackgroundInfluentialMoon, J. H., Kim, H. J., Yang, A. H., Kim, H. M., Lee, B.-W., Kang, E. S., Lee, H. C., & Cha, B. S. (2012) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001611 · Cited by 47
Matsumoto, K., Chiba, Y., Fujihara, R., Kubo, H., Sakamoto, H., & Ueno, M. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1366-7 · Cited by 46
Petralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 49
IKKβ Deficiency in Myeloid Cells Ameliorates Alzheimer's Disease-Related Symptoms and Pathology
Liu, Y., Liu, X., Hao, W., Decker, Y., Schomburg, R., Fülöp, L., Pasparakis, M., Menger, M. D., & Fassbender, K. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1348-14.2014 · Cited by 46
“We also measured A levels in the plasma and the expression of RAGE and LRP1 in the brain, two receptors that act as shuttles to transport A across the blood– brain barrier (Shibata et al., 2000; Deane et al., 2003 and 2004).”
MethodMetabolite transport across the mammalian and insect brain diffusion barriers
Weiler, A., Volkenhoff, A., Hertenstein, H., & Schirmeier, S. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.02.008 · Cited by 46
Patel, P., & Shah, J. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.06.007 · Cited by 46
“In another study, patients with PSEN1 and PSEN2 carriers demonstrated increased production of Aβ1-42, supporting the hypothesis, and reported decreased cerebrospinal fluid (CSF) Aβ42 concentration (Potter et al., 2013).”
BackgroundInfluentialJuul Rasmussen, I., Tybjærg-Hansen, A., Rasmussen, K. L., Nordestgaard, B. G., & Frikke-Schmidt, R. (2019) · European Journal of Epidemiology · doi:10.1007/s10654-019-00498-2 · Cited by 45
Zabel, M., Schrag, M., Crofton, A., Tung, S., Beaufond, P., Van Ornam, J., DiNinni, A., Vinters, H. V., Coppola, G., & Kirsch, W. M. (2013) · Brain Pathology · doi:10.1111/bpa.12005 · Cited by 46
“Two different Ab receptor/ligand complexes were studied in our post-mortem brains; the well-recognized LRP1/a2M/Ab (14, 27, 28, 37) and a new cell-surface complex, CD11b/C3b/Ab.”
BackgroundIzco, M., Martinez, P. M., Corrales, A., Fandos, N., García-Cerro, S., Insua, D., Montañés, M., Pérez‐Grijalba, V., Rueda, N., Vidal, V., et al. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.01.003 · Cited by 51
Possible role of scavenger receptor SRCL in the clearance of amyloid‐βin Alzheimer's disease
Nakamura, K., Ohya, W., Funakoshi, H., Sakaguchi, G., Kato, A., Takeda, M., Kudo, T., & Nakamura, T. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20992 · Cited by 46
Blasko, I., Kemmler, G., Krampla, W. W., Jungwirth, S., Wichart, I., Jellinger, K. A., Tragl, K. H., & Fischer, P. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.006 · Cited by 52
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Chen, J., Xiang, P., Duro-Castano, A., Cai, H., Guo, B., Liu, X., Yu, Y., Lui, S., Luo, K., Ke, B., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02426-1 · Cited by 45
Cooper, L. L., O’Donnell, A., Beiser, A., Thibault, E. G., Sanchez, J. S., Benjamin, E. J., Hamburg, N. M., Vasan, R. S., Larson, M. G., Johnson, K. A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1261 · Cited by 47
Pahnke, J., Wolkenhauer, O., Krohn, M., & Walker, L. C. (2008) · Current Alzheimer Research · doi:10.2174/156720508785132262 · Cited by 45
“Apolipoprotein E is considered to be involved in the RAGE/LRP1 shuffling mechanism [61], and polymorphisms in apolipoprotein E (ApoE) are known to markedly influence the risk of late-onset AD [53,62–68].”
BackgroundTaxifolin: A Potential Therapeutic Agent for Cerebral Amyloid Angiopathy
Saitô, S., Tanaka, M., Satoh‐Asahara, N., Carare, R. O., & Ihara, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.643357 · Cited by 47
Cholesterol and Alzheimer’s disease: Is there a link?
Koudinov, A. R., Berezov, T. T., & Koudinova, N. V. (2002) · Neurology · doi:10.1212/wnl.58.7.1135 · Cited by 45
Mare, S., Penugonda, S., Robinson, S. M., Dohgu, S., Banks, W. A., & Ercal, N. (2007) · Peptides · doi:10.1016/j.peptides.2007.05.007 · Cited by 45
Lee, A. Y., Lee, M. H., Lee, S., & Cho, E. J. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b03941 · Cited by 50
Advanced Human BBB‐on‐a‐Chip: A New Platform for Alzheimer's Disease Studies
Yoon, J., Kim, J., Shah, Z., Awasthi, A., Mahajan, A., & Kim, Y. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002285 · Cited by 49
Bhargavan, B., Woollard, S. M., Mcmillan, J. E. M., & Kanmogne, G. D. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00500-0 · Cited by 46
Upregulation of RAGE at the blood‐brain barrier in streptozotocin‐induced diabetic mice
Liu, L. P., Hong, H., Liao, J. M., Wang, T. S., Wu, J., Chen, S. S., Li, Y. Q., Long, Y., & Xia, Y. Z. (2009) · Synapse · doi:10.1002/syn.20644 · Cited by 44
“It is very interesting that downregulation of LRP1 at the BBB in diabetic mice, a inverse regulation with the RAGE, was observed in our studies (data not shown), which indicates RAGE vs. LRP1 imbalance at the BBB in the diabetes, resulting in brain Ab accumulation.”
BackgroundInfluentialData-driven modeling of Alzheimer Disease pathogenesis
Anastasio, T. J. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.08.038 · Cited by 49
Barbier, M., Faille, D., Loriod, B., Textoris, J., Camus, C., Puthier, D., Flori, L., Wassmer, S. C., Victoréro, G., Alessi, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019651 · Cited by 45
“LRP1 that binds to LRPAP1 has been shown to be involved in the clearance of the b-amyloid protein [34], which accumulates in the brain of patients with Alzheimer’s disease [35].”
BackgroundChapuis, J., Tian, J., Shi, J., Bensemain, F., Cottel, D., Lendon, C. L., Amouyel, P., Mann, D. M. A., & Lambert, J. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.013 · Cited by 48
Functional Genomics meets neurodegenerative disorders
Hoerndli, F. J., David, D. C., & Götz, J. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.07.002 · Cited by 47
Zhou, R., Chen, L.-L., Yang, H., Li, L., Liu, J., Chen, L., Hong, W.-J., Wang, C.-G., Ma, J.-J., Huang, J., et al. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210906092940 · Cited by 43
The multifaceted role of WNT signaling in Alzheimer’s disease onset and age-related progression.
Kostes, W. W., & Brafman, D. A. (2023) · Cells · doi:10.3390/cells12081204 · Cited by 43
“Aβ can be endocytosed by astrocytes through indirect or direct association with APOE in the context of several receptors mainly LDLR, LRP1, and HSPG [27–29].”
BackgroundAmyloid and Tau accumulate in the brains of aged hydrocephalic rats
Silverberg, G. D., Miller, M. C., Machan, J. T., Johanson, C. E., Caralopoulos, I. N., Pascale, C. L., Heile, A., & Klinge, P. M. (2010) · Brain Research · doi:10.1016/j.brainres.2009.12.065 · Cited by 54
Alzheimer’s Disease and the Blood–Brain Barrier: Past, Present and Future
Bowman, G. L., & Quinn, J. F. (2008) · Aging Health · doi:10.2217/1745509x.4.1.47 · Cited by 43
“LRP-1 is the main efflux transporter of Aβ across the BBB to the periphery and is expressed within the brain capillary endothelium [14,15].”
Nakajima, M., Miyajima, M., Ogino, I., Akiba, C., Sugano, H., Hara, T., Fusegi, K., Karagiozov, K. L., & Arai, H. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.07.001 · Cited by 46
High Levels of Homocysteine Results in Cerebral Amyloid Angiopathy in Mice
Li, J.-G., & Praticò, D. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141101 · Cited by 44
“Apolipoprotein E has been shown to bind directly to the A peptides and influence its fibrillogenesis and clearance in vitro [22, 23] and in vivo [24–26].”
Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes
Miners, J. S., Palmer, J. C., Tayler, H. M., Palmer, L. E., Ashby, E. L., Kehoe, P. G., & Love, S. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00238 · Cited by 50
“Soluble Aβ is cleared from the brain by multiple, diverse pathways including drainage along perivascular basement membranes (Weller et al., 1998, 2000; Preston et al., 2003) and receptor-mediated transport of Aβ across the blood-brain barrier [including transport mediated by binding to low-density lipoprotein receptor…”
BackgroundLin, H.-C., Ho, M., Tsen, C.-M., Huang, C.-C., Wu, C.-C., Huang, Y.-J., Hsiao, I., & Chuang, C. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx079 · Cited by 43
Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt–Jakob disease
Vogelgesang, S., Glatzel, M., Walker, L. C., Kroemer, H. K., Aguzzi, A., & Warzok, R. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0042-3 · Cited by 47
“It has been suggested that decreased clearance of peptides (especially Ab) from the brain at the BBB could contribute to the buildup of proteins, leading to AD and possibly to other neurodegenerative disorders such as CJD [13, 39, 48].”
BackgroundZhang, W., Xiong, H., Callaghan, D., Liu, H., Jones, A., Pei, K., Fatehi, D., Brunette, E., & Stanimirovic, D. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-13 · Cited by 41
DeCarli, C. S., Kawas, C. H., Morrison, J. H., Reuter‐Lorenz, P. A., Sperling, R. A., & Wright, C. B. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls111 · Cited by 73
Matsumoto, Y., Yanase, D., Noguchi-Shinohara, M., Ono, K., Yoshita, M., & Yamada, M. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000100019 · Cited by 42
Kölsch, H., Ptok, U., Mohamed, I., Schmitz, S., Rao, M. L., Maier, W., & Heun, R. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20043 · Cited by 43
“Both ligands bind Ab and are suggested to be crucial for Ab clearance from the brain across the blood– brain barrier via LRP [Shibata et al., 2000].”
BackgroundKim, H. J., Park, K. W., Kim, T. E., Im, J. Y., Shin, H. S., Kim, S., Lee, D. H., Ye, B. S., Kim, J. H., Kim, E.-J., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143018 · Cited by 42
The Role of Heparin and Glycocalyx in Blood–Brain Barrier Dysfunction
Yang, R., Chen, M., Zheng, J., Li, X., & Zhang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754141 · Cited by 46
“In contrast, soluble LRP and ApoE are both Ab chaperones on the cell surface, which are associated with the clearance of receptors and promote Ab extrusion from the brain back into the blood through the bloodbrain barrier (88).”
BackgroundPoliakova, T., & Wellington, C. L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00671-y · Cited by 48
“…through multiple pathways including active transport across brain endothelial cells in a process involving LDL receptor related protein (LRP1) [23], p-glycoprotein [24] and LDL receptor [25], and by perivascular drainage in mid-and large-sized arteries along smooth muscle cell basement…”
BackgroundSagare, A. P., Bell, R. D., Srivastava, A., Sengillo, J. D., Singh, I., Nishida, Y., Chow, N., & Zlokovic, B. V. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439570 · Cited by 40
Bachmeier, C., Beaulieu-Abdelahad, D., Crawford, F., Mullan, M., & Paris, D. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9866-6 · Cited by 39
Gospodarska, E., Kupniewska-Kozak, A., Goch, G., & Dadlez, M. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.02.011 · Cited by 45
La barrière hémato-encéphalique: Une nouvelle cible thérapeutique dans la maladie d’Alzheimer ?
Gosselet, F., Candela, P., Cecchelli, R., & Fénart, L. (2011) · médecine/sciences · doi:10.1051/medsci/20112711015 · Cited by 52
McIntee, F. L., Giannoni, P., Blais, S., Sommer, G., Neubert, T. A., Rostagno, A., & Ghiso, J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00223 · Cited by 42
“…2000) as well as Pglycoprotein (P-gp)—an ATP-dependent efflux pump with broad specificity also abundant in the brain capillary endothelium—are the main receptors responsible for Aβ efflux from brain-to-blood (Shibata et al., 2000; Deane et al., 2003; Candela et al., 2010; Di Marco et al., 2015).”
InfluentialSelf-citationYi, D., Lee, D. Y., Sohn, B. K., Choe, Y. M., Seo, E. H., Byun, M. S., & Woo, J. I. (2014) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.12.173 · Cited by 45
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






